NASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis $0.56 0.00 (-0.28%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.60 +0.04 (+7.14%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Century Therapeutics Stock (NASDAQ:IPSC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Century Therapeutics alerts:Sign Up Key Stats Today's Range$0.56▼$0.5850-Day Range$0.39▼$0.6052-Week Range$0.34▼$3.46Volume317,604 shsAverage Volume475,228 shsMarket Capitalization$48.25 millionP/E RatioN/ADividend YieldN/APrice Target$4.20Consensus RatingBuy Company OverviewCentury Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More… Century Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreIPSC MarketRank™: Century Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 616th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCentury Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Century Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Century Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Century Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.31% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Century Therapeutics has recently decreased by 6.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.31% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Century Therapeutics has recently decreased by 6.91%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.39 News SentimentCentury Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Century Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,285.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Century Therapeutics is held by insiders.Percentage Held by Institutions50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Century Therapeutics' insider trading history. Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSC Stock News HeadlinesCentury Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 CongressMay 28 at 4:01 PM | globenewswire.comChardan Capital Issues Optimistic Forecast for IPSC EarningsMay 23, 2025 | americanbankingnews.comElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.May 29, 2025 | Brownstone Research (Ad)Leerink Partnrs Issues Pessimistic Outlook for IPSC EarningsMay 23, 2025 | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) Price Target Cut to $6.00 by Analysts at Chardan CapitalMay 19, 2025 | americanbankingnews.comCentury Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deCentury Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comCentury Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual MeetingMay 1, 2025 | msn.comSee More Headlines IPSC Stock Analysis - Frequently Asked Questions How have IPSC shares performed this year? Century Therapeutics' stock was trading at $1.01 at the beginning of 2025. Since then, IPSC shares have decreased by 44.6% and is now trading at $0.56. View the best growth stocks for 2025 here. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings data on Thursday, May, 15th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of ($0.31) by $1.20. The firm had revenue of $109.16 million for the quarter, compared to analysts' expectations of $45.52 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative trailing twelve-month return on equity of 61.66%. When did Century Therapeutics IPO? Century Therapeutics (IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Top institutional shareholders of Century Therapeutics include Acadian Asset Management LLC (0.33%), Charles Schwab Investment Management Inc. (0.31%), Baker BROS. Advisors LP (0.28%) and Goldman Sachs Group Inc. (0.21%). Insiders that own company stock include Versant Venture Capital Vi, L, Brent Pfeiffenberger, Douglas Carr, Gregory Russotti, Adrienne Farid and Luis Borges. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Century Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/15/2025Today5/28/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IPSC CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$4.20 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+650.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$136.67 million Net Margins-4,837.73% Pretax Margin-4,869.53% Return on Equity-61.66% Return on Assets-31.78% Debt Debt-to-Equity RatioN/A Current Ratio10.39 Quick Ratio10.39 Sales & Book Value Annual Sales$114.90 million Price / Sales0.42 Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book0.18Miscellaneous Outstanding Shares86,159,000Free Float79,247,000Market Cap$48.25 million OptionableOptionable Beta1.80 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:IPSC) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.